|
[1] SCHLACHTERMAN A,CRAFT WW Jr,HILGENFELDT E,et al.Current and future treatments for hepatocellular carcinoma[J].World J Gastroenterol,2015,21(28):8478-8491.
|
|
[2] European Association for the Study of the Liver. EASL clinical practice guidelines:Drug-induced liver injury[J]. J Hepatol,2019,70(6):1222-1261.
|
|
[3] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.
|
|
[4] PARIKH ND,WALJEE AK,SINGAL AG. Downstaging hepatocellular carcinoma:A systematic review and pooled analysis[J]. Liver Transpl,2015,21(9):1142-1152.
|
|
[5] LEI JY,YAN LN,WANG WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy[J]. World J Gastroenterol,2013,19(27):4400-4408.
|
|
[6] ZHANG Y,HUANG G,WANG Y,et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization?Ten years of experience[J]. Oncologist,2016,21(12):1442-1449.
|
|
[7] JIANG L,LEI JY,WANG WT,et al. Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE[J]. J Gastrointest Surg,2014,18(6):1125-1130.
|
|
[8] LEI JY,ZHONG JJ,YAN LN,et al. Response to transarterial chemoembolization as a selection criterion for resection of hepatocellular carcinomas[J]. Br J Surg,2016,103(7):881-890.
|
|
[9] LEE BH,LEE DS,CHO CW,et al. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A[J]. World J Surg Oncol,2019,17(1):143.
|
|
[10] AFFONSO BB,GALASTRI FL,da MOTTA LEAL FILHO JM,et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or Downstaging[J]. World J Gastroenterol,2019,25(37):5687-5701.
|
|
[11] ALLARD MA,SEBAGH M,RUIZ A,et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?[J]. J Hepatol,2015,63(1):83-92.
|
|
[12] KULIK LM,ATASSI B,van HOLSBEECK L,et al. Yttrium-90microspheres(Thera Sphere)treatment of unresectable hepatocellular carcinoma:Downstaging to resection, RFA and bridge to transplantation[J]. J Surg Oncol,2006,94(7):572-586.
|
|
[13] IÑARRAIRAEGUI M,PARDO F,BILBAO JI,et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma[J].Eur J Surg Oncol,2012,38(7):594-601.
|
|
[14] LABGAA I,TABRIZIAN P,TITANO J,et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma[J]. HPB(Oxford),2019,21(11):1497-1504.
|
|
[15] LEWANDOWSKI RJ,KULIK LM,RIAZ A,et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma:Chemoembolization versus radioembolization[J]. Am J Transplant,2009,9(8):1920-1928.
|
|
[16] CHOS SH,SEONG J. Strategic application of radiotherapy for hepatocellular carcinoma[J]. Clin Mol Hepatol,2018,24(2):114-134.
|
|
[17] CHONG JU,CHOI GH,HAN DH,et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol,2018,25(11):3308-3315.
|
|
[18] LI N,FENG S,XUE J,et al. Hepatocellular carcinoma with main portal vein tumor thrombus:A comparative study comparing hepatectomy with or without neoadjuvant radiotherapy[J]. HPB(Oxford),2016,18(6):549-556.
|
|
[19] WEI X,JIANG Y,ZHANG X,et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:A randomized,open-label,multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141-2151.
|
|
[20] YOSHIMOTO T,IMURA S,MORINE Y,et al. The outcome of sorafenib therapy on unresectable hepatocellular carcinoma:Experience of conversion and salvage hepatectomy[J]. Anticancer Res,2018,38(1):501-507.
|
|
[21] HE MK,ZOU RH,LI QJ,et al. Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin,5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol,2018,41(5):734-743.
|
|
[22] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.
|
|
[23] ZAANAN A,WILLIET N,HEBBAR M,et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma:A large multicenter AGEO study[J]. J Hepatol,2013,58(1):81-88.
|
|
[24] YEO W,MOK TS,ZEE B,et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil(PIAF)combination chemotherapy for unresectable hepatocellular carcinoma[J]. J Natl Cancer Inst,2005,97(20):1532-1538.
|
|
[25] LEUNG TW,PATT YZ,LAU WY,et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma[J]. Clin Cancer Res,1999,5(7):1676-1681.
|
|
[26] KASEB AO,SHINDOH J,PATT YZ,et al. Modified cisplatin/interferonα-2b/doxorubicin/5-fluorouracil(PIAF)chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate,resectability,and survival of initially unresectable hepatocellular carcinoma[J]. Cancer,2013,119(18):3334-3342.
|
|
[27] HUANG ZP,WANG ZH,LI Y,et al. Research advances in two-step hepatectomy combining liver partition with portal vein ligation[J]. Chin J Pract Surg,2018,38(4):456-459.(in Chinese)黄智平，王志恒，李曜，等．联合肝脏分隔和门静脉结扎的二步肝切除术研究进展[J]．中国实用外科杂志，2018,38(4):456-459.
|
|
[28] CHAN A,ZHANG WY,CHOK K,et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma:A changing paradigm in modulation of future liver remnant before major hepatectomy[J]. Ann Surg, 2019.[Epub ahead of print]
|
|
[29] SCHADDE E,ARDILES V,SLANKAMENAC K,et al. ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies:Results of a multicenter analysis[J]. World J Surg,2014,38(6):1510-1519.
|
|
[30] WANG Z,PENG Y,HU J,et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma:A single center study of 45 patients[J]. Ann Surg,2018.[Epub ahead of print]
|
|
[31] PENG C,LI C,LIU C,et al. The outcome of the HCC patients underwent ALPPS:Retrospective study[J]. Medicine(Baltimore),2019,98(38):e17182.
|
|
[32] NADALIN S,CAPOBIANCO I,LI J,et al. Indications and limits for associating liver partition and portal vein ligation for staged hepatectomy(ALPPS). Lessons learned from 15 cases at a single centre[J]. Z Gastroenterol,2014,52(1):35-42.
|
|
[33] XIANG F,HU ZM. Chance and challenge of associating liver partition and portal vein ligation for staged hepatectomy[J].Hepatobiliary Pancreat Dis Int,2019,18(3):214-222.
|
|
[34] CHIA DKA,YEO Z,LOH SEK,et al. ALPPS for hepatocellular carcinoma is associated with decreased liver remnant growth[J]. J Gastrointest Surg,2018,22(6):973-980.
|
|
[35] TRUANT S,BAILLET C,DESHORGUE AC,et al. Contribution of hepatobiliary scintigraphy in assessing ALPPS most suited timing[J]. Updates Surg,2017,69(3):411-419.
|
|
[36] MELANDRO F,GIOVANARDI F,HASSAN R,et al. Minimally invasive approach in the setting of ALPPS procedure:A systematic review of the literature[J]. J Gastrointest Surg,2019,23(9):1917-1924.
|
|
[37] SIRIWARDANA RC,LO CM,CHAN SC,et al. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence:A case-control study[J]. World J Surg,2012,36(7):1640-1646.
|
|
[38] YOO H,KIM JH,KO GY,et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma[J]. Ann Surg Oncol,2011,18(5):1251-1257.
|
|
[39] TUSTUMI F,ERNANI L,COELHO FF,et al. Preoperative strategies to improve resectability for hepatocellular carcinoma:A systematic review and meta-analysis[J]. HPB(Oxford),2018,20(12):1109-1118.
|
|
[40] PENG SY,WANG XA,HUANG CY,et al. Evolution of associating liver partition and portal vein ligation for staged hepatectomy:Simpler,safer and equally effective methods[J]. World J Gastroenterol,2017,23(23):4140-4145.
|
|
[41] GARLIPP B,de BAERE T,DAMM R,et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization[J]. Hepatology,2014,59(5):1864-1873.
|
|
[42] GABR A,ABOUCHALEH N,ALI R,et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma[J]. J Vasc Interv Radiol,2018,29(11):1502-1510.
|
|
[43] CHENG H,SUN G,CHEN H,et al. Trends in the treatment of advanced hepatocellular carcinoma:Immune checkpoint blockade immunotherapy and related combination therapies[J]. Am J Cancer Res,2019,9(8):1536-1545.
|
DownLoad: